A Phase III Multicenter, Randomized, Double-Blind, Double-Dummy, Parallel-Group Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Patients With Primary Progressive Multiple Sclerosis.
This study is testing a new medication called fenebrutinib to see how well it works and if it is safe for adults with primary progressive multiple sclerosis. Researchers want to find out if it can slow down the worsening of physical disability compared to an already approved treatment called ocrelizumab.
Adults with a confirmed diagnosis of primary progressive multiple sclerosis who have experienced a worsening of physical disability over the past year may be able to join. There are specific health and age requirements, and participants in certain countries like Germany and Italy must be between 46 and 65 years old.
Participants will be randomly assigned to receive either the daily oral study pill or an infusion through a vein, along with matching dummy treatments so nobody knows which medicine they are getting. The study team will closely monitor your health, physical abilities, and safety throughout the process.
This study is taking place globally, including locations in the United States, Germany, and Italy, and it is currently active but no longer accepting new patients.
- 1Comparing a new experimental pill against a standard treatment for multiple sclerosis.
- 2Designed for adults with primary progressive multiple sclerosis who have physical disability progression.
- 3The study is currently active with all participants already enrolled.
Related video
Related links
Outside pages about this study, checked by our team
This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.